Photo Credit: iStock.com/Marco Marca
Shifting immunosuppressive trends in France revealed strong kidney transplant survival and a steady reliance on calcineurin inhibitors from 2009 to 2020.
Researchers conducted a retrospective study published in the May 2025 issue of Journal of Nephrology to describe immunosuppressive medication use and survival outcomes in patients who underwent kidney transplantation in France between 2009 and 2020.
They used data from the French national healthcare database to identify all adults who underwent kidney transplantation between 2009 and 2020. Patients were followed from transplantation until study end, death, or graft failure. Pharmacy records of immunosuppressive drug deliveries were collected. Kaplan-Meier analysis estimated survival and death-censored graft failure.
The results showed that 34,600 patients undergoing kidney transplantation were eligible, with a median follow-up of 4.0 years [IQR: 1.6–7.0 years], 5-year survival probability was 0.890 [0.885–0.895], and death-censored graft survival was 0.850 [0.844–0.856]. Survival varied by age, but graft survival did not. Calcineurin inhibitors were delivered to 29,573 patients (91.3%), antimetabolites to 29,318 (90.5%), corticosteroids to 28,536 (88.1%), mTOR inhibitors to 5,231 (16.1%), and belatacept to 1,272 (3.9%). Use of tacrolimus, everolimus, and belatacept increased, while corticosteroids, ciclosporin, and sirolimus decreased over time. Immunosuppressive treatment was maintained by 22,963 patients (76.5%) during follow-up.
Investigators concluded that kidney transplant recipients in France experienced high patient and graft survival rates, with immunosuppressive use largely stable and dominated by calcineurin inhibitors, reflecting key trends in post-transplant care and emerging therapies.
Source: link.springer.com/article/10.1007/s40620-025-02296-4
Create Post
Twitter/X Preview
Logout